DaVita (NYSE:DVA) Lowered to Hold Rating by Zacks Research

DaVita (NYSE:DVA) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

A number of other equities research analysts also recently issued reports on DVA. Truist Financial boosted their price objective on shares of DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research report on Friday, May 8th. TD Cowen upped their price target on DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research report on Monday, May 11th. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and raised their price objective for the stock from $126.00 to $220.00 in a research note on Wednesday, May 6th. Weiss Ratings reiterated a “hold (c+)” rating on shares of DaVita in a research note on Monday, June 8th. Finally, Barclays raised their target price on shares of DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $199.17.

DaVita Trading Down 0.6%

NYSE:DVA opened at $234.21 on Monday. The company has a market cap of $15.04 billion, a PE ratio of 21.73, a price-to-earnings-growth ratio of 0.77 and a beta of 0.88. The company has a 50 day simple moving average of $199.69 and a two-hundred day simple moving average of $158.21. DaVita has a 12 month low of $101.00 and a 12 month high of $239.64.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.54. The firm had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company’s revenue was up 6.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Research analysts forecast that DaVita will post 15.07 earnings per share for the current year.

Insider Activity at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the sale, the insider owned 109,194 shares of the company’s stock, valued at $22,756,029.60. The trade was a 12.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the sale, the chief financial officer directly owned 132,434 shares in the company, valued at $25,440,571.40. This trade represents a 27.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 1.50% of the company’s stock.

Institutional Trading of DaVita

A number of large investors have recently made changes to their positions in the business. Root Financial Partners LLC lifted its holdings in shares of DaVita by 128.0% in the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after acquiring an additional 105 shares during the last quarter. Elevation Wealth Partners LLC raised its position in DaVita by 147.3% during the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after purchasing an additional 165 shares during the period. Caitlin John LLC bought a new stake in shares of DaVita in the 4th quarter valued at approximately $34,000. Sankala Group LLC purchased a new position in shares of DaVita in the 4th quarter worth approximately $39,000. Finally, Canada Pension Plan Investment Board purchased a new stake in DaVita during the 2nd quarter valued at $43,000. 90.12% of the stock is currently owned by institutional investors.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.